What is the role of antibiotics, such as piperacillin-tazobactam (antibiotic) or ceftazidime (antibiotic), in patients with severe burns, particularly those with extensive tissue damage, signs of infection, or impaired renal function?

Use of Antibiotics in Burns

Primary Recommendation

Routine systemic antibiotic prophylaxis should NOT be administered to burn patients without evidence of infection, as this practice increases antimicrobial resistance without improving mortality outcomes. 1

However, when infection is suspected or confirmed (sepsis, septic shock, or documented burn wound infection), immediate empiric broad-spectrum antibiotics are essential and should be optimized using high-dose regimens with extended or continuous infusion. 1, 2

---

When to Withhold Antibiotics

No Prophylaxis in Stable Burns

• Avoid sustained systemic antibiotic prophylaxis in severe burns without signs of infection, despite the inflammatory response that mimics sepsis 1
• Meta-analyses demonstrate no clinical benefit of prophylactic antibiotics that outweighs the risk of selecting multidrug-resistant organisms 1
• The 2020 Anaesthesia guidelines explicitly recommend against routine antibiotic prophylaxis in burn patients 1
• Topical silver sulfadiazine prophylaxis actually increases burn wound infection rates (OR 1.87) and prolongs hospital stay by 2.11 days compared to dressings alone 3

Exception: Brief Perioperative Coverage

• Short-duration perioperative antibiotic prophylaxis for specific surgical procedures (excision/grafting) may be appropriate 1
• This differs from sustained prophylaxis and should be limited to the perioperative period 1

---

When to Initiate Antibiotics

Clear Indications for Treatment (Not Prophylaxis)

Antibiotics are mandatory when any of the following are present:

• Suspected or confirmed sepsis/septic shock with systemic signs (fever, hypotension, organ dysfunction) 1
• Documented burn wound infection progressing from colonization to invasive infection 2, 4
• Pneumonia, which is a leading cause of death in burn patients (infections preceded multiorgan dysfunction in 83% of fatal cases) 2
• Positive cultures with clinical deterioration 1

---

Antibiotic Selection and Dosing in Burns

Critical Pharmacokinetic Considerations

Burn patients have profoundly altered drug pharmacokinetics that render standard dosing inadequate:

• Standard piperacillin-tazobactam 4g/0.5g TID achieves only 55% time above MIC in burn patients versus 77% in other ICU patients 5
• Increased volume of distribution, augmented renal clearance, and hypermetabolic states necessitate dose escalation 5, 6

Recommended Regimens for Piperacillin-Tazobactam

For severe burns with suspected/confirmed infection:

• High-dose regimen: 8g/1g every 6 hours (QID) as 3-hour extended infusion 5, 6
• This achieves 93% time above MIC (versus 55% with standard dosing) 5
• Continuous infusion of beta-lactams shows superior outcomes in critically ill patients 1, 6

Renal adjustment required:

• Creatinine clearance <40 mL/min requires dose reduction 7
• Hemodialysis removes 30-40% of drug; additional dosing post-dialysis needed 7

Alternative Broad-Spectrum Options

For multidrug-resistant gram-negative organisms:

• Colistin has re-emerged as highly effective against resistant Pseudomonas and Acinetobacter in burns 4
• Mortality is higher in patients requiring colistin (reflecting severity), but nephrotoxicity rates are comparable to piperacillin-tazobactam 4

For ceftazidime:

• High-dose continuous infusion regimens are needed, similar to other beta-lactams 6
• Therapeutic drug monitoring is strongly recommended to ensure PK/PD target attainment 6

For gram-positive coverage:

• Vancomycin loading dose of 25-30 mg/kg (actual body weight) to rapidly achieve trough 15-20 mg/L 1
• Standard 1g loading doses fail to achieve therapeutic levels in burn patients 1

---

Therapeutic Drug Monitoring

Mandatory for optimal outcomes in burn patients:

• Beta-lactam concentrations should be monitored to ensure time above MIC targets are met 1, 6
• Aminoglycoside peak optimization (5-7 mg/kg daily for gentamicin) with trough monitoring to prevent nephrotoxicity 1
• Vancomycin trough monitoring targeting 15-20 mg/L 1

---

Special Consideration: Pneumonia Prevention

• One trial demonstrated systemic trimethoprim-sulfamethoxazole significantly reduced pneumonia (RR 0.18) in burn patients 2, 3
• However, this does not justify routine prophylaxis given resistance concerns 1
• Consider only in mechanically ventilated patients at highest risk 8

---

Critical Pitfalls to Avoid

1. Do not continue antibiotics beyond 24 hours if infection is ruled out - stop promptly to prevent resistance 1
2. Do not use standard ICU dosing - burn patients require 1.5-2x higher doses with extended/continuous infusion 5, 6
3. Do not rely on silver sulfadiazine - it increases infection rates and should be avoided 3
4. Do not ignore renal function - both burn injury and antibiotics (especially aminoglycosides, piperacillin-tazobactam) increase nephrotoxicity risk 7
5. Do not delay de-escalation - narrow or stop antibiotics based on culture results and clinical improvement 1